<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099212</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-RES-2018-01</org_study_id>
    <nct_id>NCT04099212</nct_id>
  </id_info>
  <brief_title>15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.</brief_title>
  <official_title>OBSERVATIONAL CASE-ONLY PROSPECTIVE STUDY OF EFFECTIVENESS AND SAFETY OF 15% TOPICAL RESORCINOL FOR ADULTS WITH HURLEY I-II HIDRADENITIS SUPPURATIVA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational cross-sectional study to evaluate the response of patients with HS
      I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact
      on quality of life and subclinical evolution.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the change in the disease severity</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Score change in the Hidradenitis Sartorius modified score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage profile</measure>
    <time_frame>Initial</time_frame>
    <description>Descriptive measurement of demographic and clinical variables (central tendency, dispersion and distribution of tendencies) prior to the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the security of the treatment</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Number and description of adverse effects, analysing the percentage and frequency of withdrawal and treatment suspension due to side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in the patient´s quailty of life due to the treatment</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Quantified by the average absolute change of the dermatology life quality index (DLQI) score, a questionnaire that measures the effect that the skin disease has on the quality of life of an affected person.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in the patient´s quailty of life due to the treatment 2</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Quantified by the average absolute changein the visual analog scale of pain, odor and suppuration, a scale used to measure the intensity or frequency of the symptoms related to the pain, odor and suppuration of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and partial ultrasound responders frequency of distribution.</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Change in number of fistulas, pseudocysts and abscess as well as change in doppler activity.
Defining total ultrasound responders as the ones that have a smaller number of pseudocysts, liquid collections, fistulas, smaller size and thickness of the main injury and less doppler activity than the registered in the baseline ultrasound and partial ultrasound responders as the ones that have less activity than in the baseline ultrasound in at least one of the previous variables without increase in any of the others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of responders</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Defining responder as the combination of the decrease in the abscess/nodule count by at least 50% (minimum of one), without increase in the number of draining fistulas and the number of abscesses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change in the disease severity.</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Score change in the Physician Global Assesment scale for Supurative Hidradenitis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HYDRADENITIS</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with HS I-II in monotherapy treatment of topical resorcinol 15%</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that suffer from Hs Hurley I-II from the Andalusian Public Health System that are
        been follow up by the Dermatology Unity of Clinical Management of the HUVM.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Diagnosed with HS Hurley I-II degree.

          -  Patients that have at least 1 or more swollen up nodules and/or abscess.

          -  Availability of affected region control ultrasound prior to resorcine treatment
             beginning.

        Exclusion Criteria:

          -  Age &lt; 18 years.

          -  Number of draining fistula above 20.

          -  Patients in active treatment with immunomodulators.

          -  Patients in active treatment with antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Moreno Ramírez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaime Cordero Ramos</last_name>
    <phone>600162807</phone>
    <email>jaime.cordero.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>600 162 458</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Moreno Ramírez</last_name>
      <phone>955 00 80 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RESORCINOL</keyword>
  <keyword>HIDRADENITIS SUPPURATIVA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

